Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning
This article was originally published in The Pink Sheet Daily
REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.
You may also be interested in...
FDA could use advisory committee members' comments to maintain the smoking cessation drug's boxed warning, even though they voted to remove it.
With patent erosion starting for Tracleer, its largest-selling product, Actelion outlines further details of its short- and medium-term strategy to reduce its reliance on the billion-dollar PAH therapy.
CEO Jean-Paul Clozel is seeking to rebuild investor confidence in the wake of the company's year-long run-in with activist shareholder Elliott Advisors.